Tech Company Financing Transactions
ProEncia Biotechnology Funding Round
ProEncia Biotechnology, based in Minneapolis, secured investment from private investors.
Transaction Overview
Company Name
Announced On
5/19/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
Funding will be applied to further develop, commercialize, and license a pipeline of novel, non-invasive periodontal care products designed for patients suffering from periodontal disease at all stages of severity.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Minneapolis, MN Undisclosed
USA
Minneapolis, MN Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
ProEncia is a biotech startup based in Minneapolis, MN. We were founded with a simple mission: to deliver a more effective treatment for patients who suffer from periodontal diseases. ProEncia's name comes from the latin root for promote (Pro-) and gum (-Encia), and this ethos infuses everything we do. Our team of researchers and clinicians are developing a line of safe, non-invasive, easy-to-use therapeutic products to resolve, reverse, repair, and protect against periodontal diseases, including gingivitis and chronic inflammatory auto-immune periodontitis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tapos Ghosh
Chief Operating Officer
Austin Loeb
Chief Scientific Officer
Tarun Ghosh
Browse more venture capital transactions:
Prev: 5/19/2026: SiMa.ai venture capital transaction
Next: 5/19/2026: Radar venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs